CRN-04894 is a small molecule commercialized by Crinetics Pharmaceuticals, with a leading Phase II program in Pituitary ACTH Hypersecretion (Cushing Disease). According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CRN-04894’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for CRN-04894 is expected to reach an annual total of $214 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CRN-04894 Overview
Small molecule is under development for the treatment of Cushing disease, congenital adrenal hyperplasia (CAH) and ectopic ACTH syndrome. The drug candidate is administered through oral route. The drug candidate acts by targeting adrenal corticotropic hormone (ACTH) receptor.
Crinetics Pharmaceuticals Overview
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company. It develops novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related tumors. The company’s product pipeline includes paltusotine (Oral SST2 agonist) to treat acromegaly, CRN04777 (SST5 agonist) against congenital hyperinsulinism and CRN04894 (ACTH agonist) for treatment of cushing’s disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals provides somatostatin for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia. The company also develops other drug programs to treat polycystic kidney disorders, hyperparathyroidism and obesity. Crinetics Pharmaceuticals is headquartered in San Diego, California, the US.
For a complete picture of CRN-04894’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
